Co-Diagnostics, Inc. CODX 深 滬
等待開盤 03-26 09:30:00 美东时间
1.97
-0.300
-13.22%
華盛通- 最 高2.36
- 今 開2.35
- 成交量 576.22万股
- 最 低 1.96
- 昨 收 2.27
- 總市值 412.72万
- 52周最高 3.95
- 市盈率 靜 --
- 換手率 275.04%
- 52周最低 1.96
- 委 比 96.21%
- 總股本 209.50万
- 歷史最高 3.95
- 量 比 0.49
- 振 幅 17.62%
- 歷史最低 1.96
- 每 手 1
- 風險率 0.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
Co-Diagnostics ships PCR Pro and TB test kits to India, advancing clinical studies as the WHO backs NPOC diagnostics.
03-25 19:46
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Azitra (AMEX:AZTR) stock moved upwards by 87.3% to $0.33 during Friday...
03-20 20:05
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics expands CoSara's reach across South Asia, targeting a $13 billion market and boosting access to rapid diagnostic solutions.
03-20 19:56
Co-Diagnostics Inc. schedules fourth-quarter and full-year 2025 earnings webcast
Co-Diagnostics Inc. schedules fourth-quarter and full-year 2025 earnings webcast Co-Diagnostics will release its fourth quarter and full year 2025 financial results on March 31, 2026, after the market close. The company will host a conference call and webcast on March 31, 2026 at 4:30 p.m. ET, with
03-17 21:04
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
Co-Diagnostics Granted Japanese Patent Titled 'Systems, Methods, And Apparatus For Automated Self-Contained Biological Analysis'
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Japan Patent
03-12 21:15
Co-Diagnostics Receives Japanese Patent Covering Co-Dx PCR Platform Technologies
SALT LAKE CITY, March 12, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the develo...
03-12 21:00
Co-Diagnostics Regains Nasdaq Compliance
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 9, 2026,
03-10 21:10
Maxim Group Downgrades Co-Diagnostics to Hold
Maxim Group analyst Jason McCarthy downgrades Co-Diagnostics (NASDAQ:CODX) from Buy to Hold.
01-24 02:27
Co-Diagnostics To Be Delisted From Nasdaq Effective Jan 14, 2026, After Failing Minimum $1.00 Bid Price Rule; Plans Hearing While Trading Moves To OTC Pink
On January 7, 2026, Co-Diagnostics, Inc. (the "Company") received written notice (the "Notice") from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") informing the
01-14 01:27
